Developing and testing a new oral medication in tablet form.
Official title: SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72
Funded at Irisys, INC. · NIH-11087443 · Data updated 2026-11-12
This study is working on making a new tablet medication called NCGC72 and will test it in early trials to see how safe it is and how well it works for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Irisys, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 29, 2023 |
| Project end | March 28, 2028 |
| Funding year | 2024 |
| Award (this year) | $565,585 |
| NIH project number | 271201700020I-P00001-759502300001-1 |
| Project ID | NIH-11087443 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would be individuals who are eligible for early-stage clinical trials and meet specific health criteria for the drug being tested.
✕Less likely to help
Patients who are not eligible for clinical trials or those with contraindications to the drug may not benefit from this research.
What this research studies
This research focuses on creating a solid oral dosage form, specifically tablets, for a new drug called NCGC72. The process involves developing the formulation, validating the methods used to analyze the drug products, and manufacturing pilot batches under Good Manufacturing Practices (GMP). Additionally, the research includes conducting a phase I clinical trial to assess the drug's safety and stability over time according to international guidelines. Patients may be involved in early-stage trials to evaluate the medication's effects.
Why it matters
Potential benefit: If successful, this research could lead to a new oral medication that is safe and effective for patients.
How similar studies have gone: Other research in the development of oral dosage forms has shown success, indicating that this approach is well-established in the field.
Where this research is happening
-
Irisys, INC.
San Diego, United States Active
Researchers
- Principal investigator: Giannini, Robert — Irisys, INC.
- Study coordinator: Giannini, Robert
Related research
Other NIH-funded projects on the same topics.
-
Developing and testing a new medication formulation for clinical trials.
This study is working on a new way to deliver a medication called ORC-13661, which could help patients by making the treatment more effective, and it will be tested in a clinical trial to ensure it's safe and works well.
-
Developing and testing a new oral medication formulation.
This study is working on making a new tablet medication called NCGC72, which could help patients, by ensuring it's safe, effective, and stays good for a long time before it’s tested in people.
-
Production of Z-Endoxifen capsules for treatment.
This study is working on creating a new type of capsule called Z-Endoxifen that people can take by mouth to help treat certain health conditions, making sure it's safe and effective for patients.
-
Development of a new injectable medication called TAK-243.
This study is looking at a new injectable medicine called TAK-243 to make sure it stays safe and effective for patients, so they can eventually use it in their treatment.
-
Investigating a new cancer treatment using AZA-TDC capsules.
This study is testing a new cancer treatment called AZA-TDC capsules to see how well it works and how safe it is for patients, and it's looking for people to help find out if this new option is better than what’s already available.
-
Creating capsules of ammonium tetrathiomolibdate for clinical use
This study is working on creating special capsules that contain a new treatment for patients, and it aims to make sure these capsules are safe and effective for future clinical trials.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.